CA2991779A1 - Methods for treating cancer using apilimod - Google Patents

Methods for treating cancer using apilimod Download PDF

Info

Publication number
CA2991779A1
CA2991779A1 CA2991779A CA2991779A CA2991779A1 CA 2991779 A1 CA2991779 A1 CA 2991779A1 CA 2991779 A CA2991779 A CA 2991779A CA 2991779 A CA2991779 A CA 2991779A CA 2991779 A1 CA2991779 A1 CA 2991779A1
Authority
CA
Canada
Prior art keywords
apilimod
composition
cancer
lymphoma
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2991779A
Other languages
English (en)
French (fr)
Inventor
Henri Lichenstein
Jonathan M. Rothberg
Sophia GAYLE
Neil BEEHARRY
Paul Beckett
Sean LANDRETTE
Chris Conrad
Tian Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OrphAI Therapeutics Inc
Original Assignee
LAM Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LAM Therapeutics Inc filed Critical LAM Therapeutics Inc
Publication of CA2991779A1 publication Critical patent/CA2991779A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2991779A 2015-07-20 2016-07-19 Methods for treating cancer using apilimod Abandoned CA2991779A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562194367P 2015-07-20 2015-07-20
US62/194,367 2015-07-20
PCT/US2016/042905 WO2017015262A1 (en) 2015-07-20 2016-07-19 Methods for treating cancer using apilimod

Publications (1)

Publication Number Publication Date
CA2991779A1 true CA2991779A1 (en) 2017-01-26

Family

ID=56551023

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2991779A Abandoned CA2991779A1 (en) 2015-07-20 2016-07-19 Methods for treating cancer using apilimod

Country Status (13)

Country Link
US (1) US10350213B2 (OSRAM)
EP (1) EP3325014B1 (OSRAM)
JP (2) JP2018525358A (OSRAM)
KR (1) KR20180030630A (OSRAM)
CN (1) CN108025076A (OSRAM)
AU (1) AU2016297555B2 (OSRAM)
BR (1) BR112018000776A2 (OSRAM)
CA (1) CA2991779A1 (OSRAM)
IL (1) IL256836B (OSRAM)
MX (1) MX2018000715A (OSRAM)
RU (1) RU2738934C2 (OSRAM)
TW (1) TWI746449B (OSRAM)
WO (1) WO2017015262A1 (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2937655C (en) 2014-01-24 2022-06-28 Lam Therapeutics, Inc. Apilimod compositions for cancer treatment
AU2015342863B2 (en) * 2014-11-07 2021-01-21 AI Therapeutics, Inc. Apilimod for use in the treatment of melanoma
US10206910B2 (en) 2014-11-07 2019-02-19 Lam Therapeutics, Inc. Apilimod for use in the treatment of renal cancer
TWI746449B (zh) 2015-07-20 2021-11-21 美商Ａｉ治療公司 使用阿吡莫德治療癌症之方法
JP2019502707A (ja) * 2016-01-21 2019-01-31 ラム・セラピューティクス，インコーポレーテッド 癌をアピリモドで処置するためのバイオマーカー
KR102182559B1 (ko) 2017-09-08 2020-11-24 인시그니스 쎄라퓨틱스, 인코포레이티드 디피베프린을 사용하는 방법
RU2020130837A (ru) * 2018-02-21 2022-03-21 ЭйАй ТЕРАПЬЮТИКС, ИНК. Комбинационная терапия апилимодом и глутаматергическими агентами
AU2021207804A1 (en) 2020-01-13 2022-09-01 Verge Analytics, Inc. Substituted pyrazolo-pyrimidines and uses thereof
WO2022094058A1 (en) * 2020-10-28 2022-05-05 The Regents Of The University Of Michigan Methods for preventing or treating conditions related to pikfyve activity
CN117529324A (zh) * 2021-06-11 2024-02-06 奥夫艾治疗公司 稳定的阿匹莫德组合物和其用途
WO2023108110A2 (en) * 2021-12-10 2023-06-15 Verastem, Inc. Combination therapy for treating abnormal cell growth
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
WO2025175564A1 (en) * 2024-02-23 2025-08-28 The Regents Of The University Of Michigan Method for treating autophagy dependent cancer with a pikfyve degrader

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693097B2 (en) 2001-11-30 2004-02-17 Synta Pharmaceuticals Corp. Pyrimidine compounds
CU23475A1 (es) * 2004-07-08 2009-12-17 Ct Ingenieria Genetica Biotech Composición farmacéutica conteniendo fragmentos polipeptídicos de serralisinas
US7923557B2 (en) 2004-11-10 2011-04-12 Synta Pharmaceuticals Corporation Process for preparing trisubstituted pyrimidine compounds
TW200720256A (en) 2005-05-13 2007-06-01 Synta Pharmaceuticals Corp IL-12 modulatory compounds
WO2006128129A2 (en) * 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
RU2350338C2 (ru) * 2007-05-14 2009-03-27 ФГУ Ростовский научно-исследовательский онкологический институт Росздрава Способ лечения поверхностного рака мочевого пузыря
RU2421217C2 (ru) * 2009-09-03 2011-06-20 Учреждение Российской академии медицинских наук Гематологический научный центр РАМН (ГНЦ РАМН) Способ дифференцированного лечения диффузных в-крупноклеточных лимфосарком лимфоидных органов взрослых
CA3120505C (en) * 2011-09-26 2024-11-12 Galera Labs, Llc METHODS OF TREATING DISEASES
CA2890105C (en) * 2012-11-01 2023-03-21 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
CA2902613A1 (en) * 2013-03-14 2014-10-02 Pharmacyclics Llc Combinations of bruton's tyrosine kinase inhibitors and cyp3a4 inhibitors
CN105073128A (zh) * 2013-04-03 2015-11-18 Ibc药品公司 用于诱导对疾病的免疫应答的组合疗法
JP2017501157A (ja) * 2013-12-17 2017-01-12 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニスト及び抗ｃｄ２０抗体を使用してがんを治療する方法
EP3082853A2 (en) * 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
CA2937655C (en) * 2014-01-24 2022-06-28 Lam Therapeutics, Inc. Apilimod compositions for cancer treatment
TWI746449B (zh) 2015-07-20 2021-11-21 美商Ａｉ治療公司 使用阿吡莫德治療癌症之方法

Also Published As

Publication number Publication date
JP2018525358A (ja) 2018-09-06
WO2017015262A1 (en) 2017-01-26
KR20180030630A (ko) 2018-03-23
IL256836B (en) 2021-04-29
US20170020884A1 (en) 2017-01-26
MX2018000715A (es) 2018-06-06
BR112018000776A2 (pt) 2018-09-04
JP2021121611A (ja) 2021-08-26
EP3325014A1 (en) 2018-05-30
HK1254258A1 (zh) 2019-07-12
TWI746449B (zh) 2021-11-21
TW201717957A (zh) 2017-06-01
IL256836A (en) 2018-03-29
US10350213B2 (en) 2019-07-16
RU2018105923A (ru) 2019-08-20
AU2016297555B2 (en) 2021-08-19
AU2016297555A1 (en) 2018-03-01
EP3325014B1 (en) 2021-05-19
RU2018105923A3 (OSRAM) 2019-12-20
RU2738934C2 (ru) 2020-12-18
CN108025076A (zh) 2018-05-11

Similar Documents

Publication Publication Date Title
AU2016297555B2 (en) Methods for treating cancer using apilimod
US11266654B2 (en) Apilimod compositions and methods for using same
US20180078561A1 (en) Active metabolites of apilimod and uses thereof
AU2015342876B2 (en) Apilimod for use in the treatment of colorectal cancer
HK1254258B (en) Methods for treating cancer using apilimod
HK1226329B (en) Apilimod compositions for treating non-hodgkin's b cell lymphoma
NZ722491B2 (en) Apilimod compositions and methods for using same
HK1242965B (en) Apilimod for use in the treatment of colorectal cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210707

EEER Examination request

Effective date: 20210707

EEER Examination request

Effective date: 20210707

EEER Examination request

Effective date: 20210707

FZDE Discontinued

Effective date: 20240116